Carsten Thiel was raised in Berlin. He grew up in Germany. The budding healthcare professional was bright at school. He pursued chemistry in Malbrook. Thiel had the desire to understand the Anglo-Saxon system of education. He, therefore, left his native capital to enroll at the prestigious Bristol University. Thiel pursued organic chemistry. He received his degree in science, and further specialized in biotechnology. He also pursued biochemistry. Eventually, he enrolled at Max Planck School of Chemistry, where he took up a Ph.D. in biology. He concentrated his unit in protein associated with the health of cells.
After completing his studies, he delved into his initial foray, where he joined the pharmaceutical industry. He landed his first employment opportunity at Hoffman La-Roche, a prominent biotechnology firm. At first, he served as the firm’s communications manager. Thiel registered excellent performance. Therefore, he was promoted to serve as a product manager. With his newly garnered experience, he could now carve an excellent reputation for himself. Soon after, Thiel was tasked with the responsibility of overseeing the scientific department of the firm. He also took over market assessment.
Thiel has since been defined as the man behind the development of the biotechnology industry. He has served as the GM of Insadong. He has also exuded many years of experience when it comes to launching products. Thiel has a strong conviction when it comes to following ethics at work. He believes that every employee should be treated as humanely as possible. He has also proven to be a great business leader. As such, EUSA Pharma, a leading biotechnology firm, has appointed him to serve as the president. He will oversee the clinical development segment. EUSA Pharma is a dynamic biotechnological firm that is focused on oncology in addition to a rare disease. The organization continuously strives to confront various gaps found in patient care.
JD.com is the largest retailer, and it launched its tracing solution that will help pharmaceutical companies in China provide more transparency to their customers. This tracing solution is a blockchain technology-based, and it is available on JD Blockchain Open Platform. JD.com announced this move in Beijing 2018 at their Big Data Summit. There have been many concerns in China about the authenticity and transparency in the medical field. JD.com wishes to address this authenticity by launching this Medicine Tracing Solution that will provide transparent and reliable tracing information to the customers in China. This tracing solution is meant to cover every single step of drugs from the production, transportation, storage, sale, and medical application. The tracing solution has a very friendly user interface that customers can use easily, and it uses the Internet of Things also to improve the collection of data.
JD.com decided to venture into the pharmaceutical chain after there was an array of incidents in China were the pharmaceutical products were substandard and unsafe. This was especially in the field of vaccination where most vaccines were found to be below the safety standards or even expired. This caused a growing concern to the customers on the safety of the medicines that they were consuming and its origins. JD.com has teamed up with other partners in the pharmaceutical industry such as medical software providers and smart hardware manufacturers to create an IoT that promotes traceability. This will lead to an increase in transparency in the pharmaceutical industry as well as raise the standards of the drugs that are being manufactured. JD.com mains goal is that all individuals are accountable and are transparent which includes businesses, consumers as well as the government.
JD.com wants to use its technology to allow for the collection of accurate, reliable and transparent information about how drugs are sourced right to their selling. This blockchain tracing solution will go a long way in helping the consumers of China get access to safe and quality medicine. This way, there will be no future incidences of unsafe medication that will cost the health of a consumer.
Details JD via Twitter : https://twitter.com/jd_corporate